25 XP   0   0   10

Daewoong Pharma
Buy, Hold or Sell?

Let's analyse Daewoong together

PenkeI guess you are interested in Daewoong Pharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Daewoong Pharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Daewoong Pharma

I send you an email if I find something interesting about Daewoong Pharma.

Quick analysis of Daewoong (30 sec.)










What can you expect buying and holding a share of Daewoong? (30 sec.)

How much money do you get?

How much money do you get?
₩0.90
When do you have the money?
1 year
How often do you get paid?
85.0%

What is your share worth?

Current worth
₩74,326.89
Expected worth in 1 year
₩82,831.39
How sure are you?
87.5%

+ What do you gain per year?

Total Gains per Share
₩9,787.84
Return On Investment
8.8%

For what price can you sell your share?

Current Price per Share
₩111,700.00
Expected price per share
₩104,900 - ₩138,500
How sure are you?
50%

1. Valuation of Daewoong (5 min.)




Live pricePrice per Share (EOD)

₩111,700.00

Intrinsic Value Per Share

₩-33,282.14 - ₩-931.37

Total Value Per Share

₩41,044.75 - ₩73,395.52

2. Growth of Daewoong (5 min.)




Is Daewoong growing?

Current yearPrevious yearGrowGrow %
How rich?$598.6m$509.5m$53.5m9.5%

How much money is Daewoong making?

Current yearPrevious yearGrowGrow %
Making money$8.1m$14.3m-$6.2m-77.4%
Net Profit Margin3.4%6.6%--

How much money comes from the company's main activities?

3. Financial Health of Daewoong (5 min.)




What can you expect buying and holding a share of Daewoong? (5 min.)

Welcome investor! Daewoong's management wants to use your money to grow the business. In return you get a share of Daewoong.

What can you expect buying and holding a share of Daewoong?

First you should know what it really means to hold a share of Daewoong. And how you can make/lose money.

Speculation

The Price per Share of Daewoong is ₩111,700. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Daewoong.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Daewoong, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩74,326.89. Based on the TTM, the Book Value Change Per Share is ₩2,126.13 per quarter. Based on the YOY, the Book Value Change Per Share is ₩1,821.94 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩320.84 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Daewoong.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.950.0%0.710.0%1.250.0%0.400.0%0.440.0%
Usd Book Value Change Per Share1.840.0%1.490.0%1.280.0%0.660.0%0.650.0%
Usd Dividend Per Share0.040.0%0.220.0%0.120.0%0.220.0%0.280.0%
Usd Total Gains Per Share1.880.0%1.710.0%1.390.0%0.880.0%0.930.0%
Usd Price Per Share78.96-82.74-113.14-100.33-86.36-
Price to Earnings Ratio20.83-0.72-24.94-58.74-55.91-
Price-to-Total Gains Ratio42.01--6.60-92.02-163.93--140.55-
Price to Book Ratio1.52-1.71-2.56-2.40-2.26-
Price-to-Total Gains Ratio42.01--6.60-92.02-163.93--140.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share78.19
Number of shares12
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.220.22
Usd Book Value Change Per Share1.490.66
Usd Total Gains Per Share1.710.88
Gains per Quarter (12 shares)20.5510.61
Gains per Year (12 shares)82.2242.44
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1117172113232
222143154226374
3322142363295116
44328631843127158
55435740054158200
66542948265190242
77550056475222284
88657264686253326
99764372897285368
10108714810108317410

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%10.02.00.083.3%16.04.00.080.0%35.04.01.087.5%38.04.01.088.4%
Book Value Change Per Share3.01.00.075.0%9.03.00.075.0%15.05.00.075.0%31.09.00.077.5%34.09.00.079.1%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%18.00.02.090.0%34.00.06.085.0%36.00.07.083.7%
Total Gains per Share3.01.00.075.0%10.02.00.083.3%16.04.00.080.0%35.05.00.087.5%38.05.00.088.4%

Fundamentals of Daewoong

About Daewoong Pharma

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-15 11:34:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Daewoong Pharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Daewoong earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Daewoong to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 4.6% means that ₩0.05 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Daewoong Pharma:

  • The MRQ is 4.6%. The company is making a profit. +1
  • The TTM is 3.4%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ4.6%TTM3.4%+1.2%
TTM3.4%YOY6.6%-3.2%
TTM3.4%5Y2.0%+1.4%
5Y2.0%10Y2.9%-0.9%
1.1.2. Return on Assets

Shows how efficient Daewoong is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Daewoong to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.9% Return on Assets means that Daewoong generated ₩0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Daewoong Pharma:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.7%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.9%TTM0.7%+0.2%
TTM0.7%YOY1.4%-0.7%
TTM0.7%5Y0.4%+0.3%
5Y0.4%10Y0.7%-0.3%
1.1.3. Return on Equity

Shows how efficient Daewoong is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Daewoong to the Drug Manufacturers - Specialty & Generic industry mean.
  • 2.2% Return on Equity means Daewoong generated ₩0.02 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Daewoong Pharma:

  • The MRQ is 2.2%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ2.2%TTM1.6%+0.6%
TTM1.6%YOY3.4%-1.8%
TTM1.6%5Y1.0%+0.6%
5Y1.0%10Y1.4%-0.3%

1.2. Operating Efficiency of Daewoong Pharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Daewoong is operating .

  • Measures how much profit Daewoong makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Daewoong to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Daewoong Pharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM5.7%-5.7%
TTM5.7%YOY8.6%-2.9%
TTM5.7%5Y6.0%-0.3%
5Y6.0%10Y3.7%+2.3%
1.2.2. Operating Ratio

Measures how efficient Daewoong is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.43 means that the operating costs are ₩1.43 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Daewoong Pharma:

  • The MRQ is 1.430. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.215. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.430TTM1.215+0.215
TTM1.215YOY1.2150.000
TTM1.2155Y1.343-0.128
5Y1.34310Y1.158+0.185

1.3. Liquidity of Daewoong Pharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Daewoong is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.91 means the company has ₩0.91 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Daewoong Pharma:

  • The MRQ is 0.912. The company is just not able to pay all its short-term debts. -1
  • The TTM is 1.084. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.912TTM1.084-0.171
TTM1.084YOY1.249-0.165
TTM1.0845Y1.469-0.385
5Y1.46910Y1.117+0.351
1.3.2. Quick Ratio

Measures if Daewoong is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Daewoong to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.25 means the company can pay off ₩0.25 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Daewoong Pharma:

  • The MRQ is 0.246. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.363. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.246TTM0.363-0.117
TTM0.363YOY0.506-0.143
TTM0.3635Y0.665-0.302
5Y0.66510Y0.843-0.178

1.4. Solvency of Daewoong Pharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Daewoong assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Daewoong to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.50 means that Daewoong assets are financed with 50.0% credit (debt) and the remaining percentage (100% - 50.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Daewoong Pharma:

  • The MRQ is 0.500. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.510. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.500TTM0.510-0.010
TTM0.510YOY0.507+0.003
TTM0.5105Y0.502+0.008
5Y0.50210Y0.449+0.053
1.4.2. Debt to Equity Ratio

Measures if Daewoong is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Daewoong to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 121.3% means that company has ₩1.21 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Daewoong Pharma:

  • The MRQ is 1.213. The company is able to pay all its debts with equity. +1
  • The TTM is 1.259. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.213TTM1.259-0.047
TTM1.259YOY1.244+0.015
TTM1.2595Y1.237+0.022
5Y1.23710Y1.024+0.213

2. Market Valuation of Daewoong Pharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Daewoong generates.

  • Above 15 is considered overpriced but always compare Daewoong to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 20.83 means the investor is paying ₩20.83 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Daewoong Pharma:

  • The EOD is 20.625. Based on the earnings, the company is fair priced.
  • The MRQ is 20.828. Based on the earnings, the company is fair priced.
  • The TTM is 0.724. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD20.625MRQ20.828-0.203
MRQ20.828TTM0.724+20.104
TTM0.724YOY24.938-24.215
TTM0.7245Y58.736-58.012
5Y58.73610Y55.913+2.822
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Daewoong Pharma:

  • The EOD is 12.799. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 12.925. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 8.059. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD12.799MRQ12.925-0.126
MRQ12.925TTM8.059+4.866
TTM8.059YOY351.658-343.598
TTM8.0595Y100.111-92.052
5Y100.11110Y41.786+58.326
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Daewoong is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.52 means the investor is paying ₩1.52 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Daewoong Pharma:

  • The EOD is 1.503. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.518. Based on the equity, the company is underpriced. +1
  • The TTM is 1.711. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.503MRQ1.518-0.015
MRQ1.518TTM1.711-0.193
TTM1.711YOY2.555-0.845
TTM1.7115Y2.404-0.694
5Y2.40410Y2.259+0.145
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Daewoong Pharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2629.5482126.125+24%1821.938+44%942.905+179%923.510+185%
Book Value Per Share--74326.88969903.379+6%63260.290+17%60615.883+23%54343.079+37%
Current Ratio--0.9121.084-16%1.249-27%1.469-38%1.117-18%
Debt To Asset Ratio--0.5000.510-2%0.507-1%0.502-1%0.449+11%
Debt To Equity Ratio--1.2131.259-4%1.244-2%1.237-2%1.024+18%
Dividend Per Share--55.560320.835-83%169.101-67%320.310-83%401.816-86%
Eps--1353.9271007.732+34%1787.342-24%567.102+139%631.448+114%
Free Cash Flow Per Share--2181.784907.926+140%-297.025+114%348.151+527%-664.622+130%
Free Cash Flow To Equity Per Share--2181.784-567.286+126%68.044+3106%539.003+305%710.843+207%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.975+3%
Intrinsic Value_10Y_max---931.371--------
Intrinsic Value_10Y_min---33282.140--------
Intrinsic Value_1Y_max--87.335--------
Intrinsic Value_1Y_min---2791.254--------
Intrinsic Value_3Y_max--124.719--------
Intrinsic Value_3Y_min---8907.311--------
Intrinsic Value_5Y_max---3.893--------
Intrinsic Value_5Y_min---15547.191--------
Market Cap1285253710000.000-1%1297910640000.0001360044660000.000-5%1859705737500.000-30%1649140447500.000-21%1419474699500.000-9%
Net Profit Margin--0.0460.034+35%0.066-30%0.020+130%0.029+58%
Operating Margin---0.057-100%0.086-100%0.060-100%0.037-100%
Operating Ratio--1.4301.215+18%1.215+18%1.343+7%1.158+24%
Pb Ratio1.503-1%1.5181.711-11%2.555-41%2.404-37%2.259-33%
Pe Ratio20.625-1%20.8280.724+2777%24.938-16%58.736-65%55.913-63%
Price Per Share111700.000-1%112800.000118200.000-5%161625.000-30%143325.000-21%123365.000-9%
Price To Free Cash Flow Ratio12.799-1%12.9258.059+60%351.658-96%100.111-87%41.786-69%
Price To Total Gains Ratio41.600-1%42.009-6.596+116%92.018-54%163.928-74%-140.550+435%
Quick Ratio--0.2460.363-32%0.506-51%0.665-63%0.843-71%
Return On Assets--0.0090.007+32%0.014-35%0.004+117%0.007+32%
Return On Equity--0.0220.016+34%0.034-36%0.010+117%0.014+63%
Total Gains Per Share--2685.1082446.960+10%1991.039+35%1263.215+113%1325.326+103%
Usd Book Value--598659240.746563030473.063+6%509524309.047+17%488225172.327+23%437701440.713+37%
Usd Book Value Change Per Share--1.8411.488+24%1.275+44%0.660+179%0.646+185%
Usd Book Value Per Share--52.02948.932+6%44.282+17%42.431+23%38.040+37%
Usd Dividend Per Share--0.0390.225-83%0.118-67%0.224-83%0.281-86%
Usd Eps--0.9480.705+34%1.251-24%0.397+139%0.442+114%
Usd Free Cash Flow--17572980.6777312809.305+140%-2392357.681+114%2804149.496+527%-5219308.045+130%
Usd Free Cash Flow Per Share--1.5270.636+140%-0.208+114%0.244+527%-0.465+130%
Usd Free Cash Flow To Equity Per Share--1.527-0.397+126%0.048+3106%0.377+305%0.498+207%
Usd Market Cap899677597.000-1%908537448.000952031262.000-5%1301794016.250-30%1154398313.250-21%993632289.650-9%
Usd Price Per Share78.190-1%78.96082.740-5%113.138-30%100.328-21%86.356-9%
Usd Profit--10905079.8648116682.919+34%14395984.423-24%4567670.958+139%5085944.037+114%
Usd Revenue--238629834.163234725721.888+2%219681887.672+9%206073932.425+16%179429889.620+33%
Usd Total Gains Per Share--1.8801.713+10%1.394+35%0.884+113%0.928+103%
 EOD+4 -4MRQTTM+24 -11YOY+19 -165Y+25 -1010Y+25 -11

3.2. Fundamental Score

Let's check the fundamental score of Daewoong Pharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1520.625
Price to Book Ratio (EOD)Between0-11.503
Net Profit Margin (MRQ)Greater than00.046
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.246
Current Ratio (MRQ)Greater than10.912
Debt to Asset Ratio (MRQ)Less than10.500
Debt to Equity Ratio (MRQ)Less than11.213
Return on Equity (MRQ)Greater than0.150.022
Return on Assets (MRQ)Greater than0.050.009
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Daewoong Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose111,700.000
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Net Working Capital  146,922,243-70,785,34076,136,90317,302,13993,439,042-52,834,67440,604,368-97,874,840-57,270,472



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets1,709,101,199
Total Liabilities853,873,713
Total Stockholder Equity704,157,166
 As reported
Total Liabilities 853,873,713
Total Stockholder Equity+ 704,157,166
Total Assets = 1,709,101,199

Assets

Total Assets1,709,101,199
Total Current Assets596,136,438
Long-term Assets1,112,964,762
Total Current Assets
Cash And Cash Equivalents 143,777,701
Short-term Investments 28,207,973
Net Receivables 132,344,034
Inventory 233,220,809
Other Current Assets 17,493,863
Total Current Assets  (as reported)596,136,438
Total Current Assets  (calculated)555,044,380
+/- 41,092,058
Long-term Assets
Property Plant Equipment 474,010,652
Intangible Assets 292,301,877
Long-term Assets Other 9,376,028
Long-term Assets  (as reported)1,112,964,762
Long-term Assets  (calculated)775,688,557
+/- 337,276,205

Liabilities & Shareholders' Equity

Total Current Liabilities653,406,909
Long-term Liabilities200,466,803
Total Stockholder Equity704,157,166
Total Current Liabilities
Short Long Term Debt 358,614,101
Accounts payable 99,074,296
Other Current Liabilities 0
Total Current Liabilities  (as reported)653,406,909
Total Current Liabilities  (calculated)457,688,397
+/- 195,718,512
Long-term Liabilities
Long term Debt 50,000,000
Capital Lease Obligations Min Short Term Debt4,268,261
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)200,466,803
Long-term Liabilities  (calculated)54,268,261
+/- 146,198,542
Total Stockholder Equity
Retained Earnings 553,383,104
Total Stockholder Equity (as reported)704,157,166
Total Stockholder Equity (calculated)553,383,104
+/- 150,774,063
Other
Capital Stock28,966,438
Common Stock Shares Outstanding 11,506
Net Debt 264,836,400
Net Invested Capital 1,112,771,267
Net Working Capital -57,270,472
Property Plant and Equipment Gross 474,010,652



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
511,044,000
511,397,708
530,363,048
579,012,972
589,820,458
595,675,235
614,681,228
694,263,908
711,189,804
732,899,615
958,383,640
944,529,005
950,345,565
1,072,523,853
1,067,443,457
1,144,699,986
1,141,066,410
1,159,124,033
1,186,557,009
1,213,524,544
1,215,202,725
1,223,159,148
1,223,823,190
1,207,846,352
1,215,709,567
1,233,033,382
1,245,777,170
1,245,668,149
1,274,550,094
1,250,486,026
1,336,492,947
1,366,907,921
1,421,432,249
1,390,397,387
1,400,323,100
1,415,179,681
1,455,842,712
1,496,947,622
1,540,151,303
1,563,340,614
1,644,679,317
1,646,043,499
1,709,101,199
1,709,101,1991,646,043,4991,644,679,3171,563,340,6141,540,151,3031,496,947,6221,455,842,7121,415,179,6811,400,323,1001,390,397,3871,421,432,2491,366,907,9211,336,492,9471,250,486,0261,274,550,0941,245,668,1491,245,777,1701,233,033,3821,215,709,5671,207,846,3521,223,823,1901,223,159,1481,215,202,7251,213,524,5441,186,557,0091,159,124,0331,141,066,4101,144,699,9861,067,443,4571,072,523,853950,345,565944,529,005958,383,640732,899,615711,189,804694,263,908614,681,228595,675,235589,820,458579,012,972530,363,048511,397,708511,044,000
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
507,458,546
490,022,401
504,417,417
494,712,484
518,131,858
524,048,077
537,836,303
527,145,462
515,665,941
511,245,187
529,764,097
544,804,514
526,256,347
559,007,439
525,480,360
514,372,964
528,351,295
593,890,787
529,722,497
543,962,889
524,893,678
538,548,996
569,487,360
584,643,839
548,968,364
597,243,762
570,945,021
596,136,438
596,136,438570,945,021597,243,762548,968,364584,643,839569,487,360538,548,996524,893,678543,962,889529,722,497593,890,787528,351,295514,372,964525,480,360559,007,439526,256,347544,804,514529,764,097511,245,187515,665,941527,145,462537,836,303524,048,077518,131,858494,712,484504,417,417490,022,401507,458,546000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
78,280,444
58,536,073
92,491,757
78,960,977
91,121,303
67,584,926
47,679,427
29,484,020
65,333,695
64,645,949
45,894,656
62,850,857
32,094,194
77,245,834
73,873,130
70,241,086
72,299,250
97,910,273
61,136,530
84,212,464
75,907,306
135,959,762
121,966,686
133,053,962
102,951,260
140,847,943
112,501,882
143,777,701
143,777,701112,501,882140,847,943102,951,260133,053,962121,966,686135,959,76275,907,30684,212,46461,136,53097,910,27372,299,25070,241,08673,873,13077,245,83432,094,19462,850,85745,894,65664,645,94965,333,69529,484,02047,679,42767,584,92691,121,30378,960,97792,491,75758,536,07378,280,444000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
82,554,264
95,695,410
68,154,892
55,091,372
55,951,755
75,189,162
74,728,495
24,841,997
67,042,664
66,449,070
93,677,614
109,870,572
97,736,962
89,285,851
82,324,864
81,475,826
104,820,752
121,414,736
118,077,713
104,749,372
97,826,593
43,460,952
48,581,455
49,532,492
37,699,587
37,948,276
38,110,961
28,207,973
28,207,97338,110,96137,948,27637,699,58749,532,49248,581,45543,460,95297,826,593104,749,372118,077,713121,414,736104,820,75281,475,82682,324,86489,285,85197,736,962109,870,57293,677,61466,449,07067,042,66424,841,99774,728,49575,189,16255,951,75555,091,37268,154,89295,695,41082,554,264000000000000000
       Net Receivables 
0
90,624,324
0
89,365,008
98,330,445
103,370,099
104,883,457
102,254,401
104,724,664
122,585,841
147,751,085
142,159,461
140,676,478
149,682,778
148,322,470
172,887,424
157,114,034
161,152,666
178,076,871
169,609,754
166,223,688
188,609,190
178,985,303
178,888,187
165,039,296
183,980,770
149,329,321
205,735,802
184,936,003
160,611,310
154,360,291
147,577,645
161,147,536
149,698,729
156,542,289
159,507,587
157,728,571
176,065,367
166,952,969
179,144,175
132,636,957
178,947,328
132,344,034
132,344,034178,947,328132,636,957179,144,175166,952,969176,065,367157,728,571159,507,587156,542,289149,698,729161,147,536147,577,645154,360,291160,611,310184,936,003205,735,802149,329,321183,980,770165,039,296178,888,187178,985,303188,609,190166,223,688169,609,754178,076,871161,152,666157,114,034172,887,424148,322,470149,682,778140,676,478142,159,461147,751,085122,585,841104,724,664102,254,401104,883,457103,370,09998,330,44589,365,008090,624,3240
       Inventory 
85,867,127
91,679,369
101,265,494
115,144,354
116,971,328
119,609,496
117,010,951
111,864,089
117,537,530
124,861,471
142,783,474
144,507,851
133,748,311
161,211,180
170,204,267
162,746,111
168,539,738
170,715,381
172,791,507
187,015,618
196,407,368
204,675,054
216,292,718
189,035,192
179,125,017
168,909,951
173,156,351
177,609,256
192,691,128
193,860,501
180,619,255
173,970,643
180,813,600
181,645,704
181,900,410
175,051,532
184,099,996
199,277,579
210,406,559
208,735,654
229,005,486
227,115,935
233,220,809
233,220,809227,115,935229,005,486208,735,654210,406,559199,277,579184,099,996175,051,532181,900,410181,645,704180,813,600173,970,643180,619,255193,860,501192,691,128177,609,256173,156,351168,909,951179,125,017189,035,192216,292,718204,675,054196,407,368187,015,618172,791,507170,715,381168,539,738162,746,111170,204,267161,211,180133,748,311144,507,851142,783,474124,861,471117,537,530111,864,089117,010,951119,609,496116,971,328115,144,354101,265,49491,679,36985,867,127
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
704,464,380
703,269,285
700,972,656
719,411,803
715,542,654
725,005,666
812,619,623
838,556,626
827,541,463
860,674,890
856,360,210
890,286,003
917,293,715
927,460,262
955,507,464
1,014,372,250
1,047,435,556
1,075,098,478
1,112,964,762
1,112,964,7621,075,098,4781,047,435,5561,014,372,250955,507,464927,460,262917,293,715890,286,003856,360,210860,674,890827,541,463838,556,626812,619,623725,005,666715,542,654719,411,803700,972,656703,269,285704,464,380000000000000000000000000
       Property Plant Equipment 
116,546,659
118,416,838
118,329,415
132,623,043
133,737,066
138,788,423
148,742,094
160,109,521
178,440,618
187,429,555
237,101,699
255,844,142
269,059,205
302,927,804
341,727,315
367,079,907
382,178,556
385,518,219
395,155,637
396,157,724
394,642,261
392,394,495
406,838,771
401,129,322
404,011,267
402,614,037
396,826,156
391,708,052
387,079,233
385,807,536
392,169,432
393,690,454
389,130,303
389,431,180
391,006,686
395,866,259
406,852,627
406,773,000
432,380,091
440,889,685
450,008,077
459,493,981
474,010,652
474,010,652459,493,981450,008,077440,889,685432,380,091406,773,000406,852,627395,866,259391,006,686389,431,180389,130,303393,690,454392,169,432385,807,536387,079,233391,708,052396,826,156402,614,037404,011,267401,129,322406,838,771392,394,495394,642,261396,157,724395,155,637385,518,219382,178,556367,079,907341,727,315302,927,804269,059,205255,844,142237,101,699187,429,555178,440,618160,109,521148,742,094138,788,423133,737,066132,623,043118,329,415118,416,838116,546,659
       Goodwill 
83,623
83,622
83,622
83,622
83,622
0
0
83,622
0
83,622
60,848,078
60,848,079
60,848,079
60,848,079
60,848,079
60,848,079
60,848,079
60,848,079
60,848,079
60,848,079
60,848,079
60,848,079
60,848,079
60,848,079
0
0
0
60,848,079
0
0
0
60,848,079
0
0
0
60,848,079
0
0
0
60,848,079
0
0
0
00060,848,07900060,848,07900060,848,07900060,848,07900060,848,07960,848,07960,848,07960,848,07960,848,07960,848,07960,848,07960,848,07960,848,07960,848,07960,848,07960,848,07960,848,07960,848,07883,622083,6220083,62283,62283,62283,62283,623
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,670,809
9,794,995
9,002,739
8,768,355
8,046,860
8,143,760
11,239,672
10,705,637
18,123,292
26,351,351
26,345,675
25,609,784
32,144,193
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000032,144,19325,609,78426,345,67526,351,35118,123,29210,705,63711,239,6728,143,7608,046,8608,768,3559,002,7399,794,9958,670,809000000000000000
       Intangible Assets 
29,161,899
28,316,688
27,994,783
27,760,021
27,607,022
28,115,941
28,899,719
31,409,592
31,609,589
31,689,233
115,965,568
113,495,932
125,762,990
124,869,948
128,911,637
127,632,838
126,819,376
127,836,556
154,723,050
152,797,770
151,288,072
87,583,499
85,751,622
82,690,136
151,835,405
154,354,426
159,941,963
103,837,733
166,004,498
167,344,725
172,054,451
117,893,807
184,834,032
206,824,879
211,830,304
164,320,663
232,825,678
247,797,629
256,182,035
205,159,639
278,720,647
283,643,099
292,301,877
292,301,877283,643,099278,720,647205,159,639256,182,035247,797,629232,825,678164,320,663211,830,304206,824,879184,834,032117,893,807172,054,451167,344,725166,004,498103,837,733159,941,963154,354,426151,835,40582,690,13685,751,62287,583,499151,288,072152,797,770154,723,050127,836,556126,819,376127,632,838128,911,637124,869,948125,762,990113,495,932115,965,56831,689,23331,609,58931,409,59228,899,71928,115,94127,607,02227,760,02127,994,78328,316,68829,161,899
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,928,497
5,470,547
5,224,680
0
4,443,622
4,219,485
3,723,681
1
2,723,266
5,922,384
6,067,583
0
6,209,664
6,249,602
6,414,225
-1
7,765,615
9,871,192
9,376,028
9,376,0289,871,1927,765,615-16,414,2256,249,6026,209,66406,067,5835,922,3842,723,26613,723,6814,219,4854,443,62205,224,6805,470,5474,928,497000000000000000000000000
> Total Liabilities 
116,969,473
99,082,532
100,182,842
141,049,551
141,444,779
134,513,310
160,407,829
238,757,925
254,556,701
261,304,835
382,112,326
364,288,461
369,868,739
489,548,866
484,515,201
540,148,895
542,765,446
547,535,685
562,167,392
581,987,525
585,577,865
587,571,452
585,582,742
600,036,902
604,461,749
610,905,374
617,481,180
609,748,055
610,708,235
594,666,296
671,275,422
671,659,305
731,973,244
718,496,388
726,806,026
712,772,242
741,483,597
759,518,849
782,779,150
822,117,616
848,783,935
821,072,377
853,873,713
853,873,713821,072,377848,783,935822,117,616782,779,150759,518,849741,483,597712,772,242726,806,026718,496,388731,973,244671,659,305671,275,422594,666,296610,708,235609,748,055617,481,180610,905,374604,461,749600,036,902585,582,742587,571,452585,577,865581,987,525562,167,392547,535,685542,765,446540,148,895484,515,201489,548,866369,868,739364,288,461382,112,326261,304,835254,556,701238,757,925160,407,829134,513,310141,444,779141,049,551100,182,84299,082,532116,969,473
   > Total Current Liabilities 
97,672,107
75,608,592
73,815,006
87,196,834
84,372,307
76,943,712
100,289,274
79,679,838
92,588,976
97,898,608
110,774,797
149,436,907
152,303,999
166,645,058
158,379,534
222,832,140
225,701,029
229,505,703
332,586,274
268,048,604
271,372,871
372,911,916
280,951,897
367,400,665
368,398,504
269,348,427
276,492,681
262,080,186
263,395,156
249,692,239
410,418,851
326,750,097
381,587,728
447,622,624
371,420,597
460,659,801
472,441,620
412,192,318
437,721,596
472,831,460
503,804,720
530,340,653
653,406,909
653,406,909530,340,653503,804,720472,831,460437,721,596412,192,318472,441,620460,659,801371,420,597447,622,624381,587,728326,750,097410,418,851249,692,239263,395,156262,080,186276,492,681269,348,427368,398,504367,400,665280,951,897372,911,916271,372,871268,048,604332,586,274229,505,703225,701,029222,832,140158,379,534166,645,058152,303,999149,436,907110,774,79797,898,60892,588,97679,679,838100,289,27476,943,71284,372,30787,196,83473,815,00675,608,59297,672,107
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
396,917,806
394,852,193
396,139,874
189,892,039
89,936,158
89,959,436
189,873,645
99,918,010
199,864,886
208,744,218
108,838,778
108,437,977
99,336,163
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000099,336,163108,437,977108,838,778208,744,218199,864,88699,918,010189,873,64589,959,43689,936,158189,892,039396,139,874394,852,193396,917,806000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
396,917,806
394,852,193
396,139,874
189,892,039
89,936,158
89,959,436
189,873,645
99,918,010
199,864,886
208,122,891
108,838,778
108,437,977
99,336,163
96,822,777
96,433,409
236,126,646
146,978,543
146,318,051
244,433,632
154,412,803
255,987,044
254,772,828
191,786,177
194,256,688
233,672,798
232,451,510
268,595,546
358,614,101
358,614,101268,595,546232,451,510233,672,798194,256,688191,786,177254,772,828255,987,044154,412,803244,433,632146,318,051146,978,543236,126,64696,433,40996,822,77799,336,163108,437,977108,838,778208,122,891199,864,88699,918,010189,873,64589,959,43689,936,158189,892,039396,139,874394,852,193396,917,806000000000000000
       Accounts payable 
0
30,435,559
0
35,520,645
31,089,531
31,413,425
33,573,899
36,486,868
35,298,092
43,511,470
42,851,309
45,467,489
0
69,709,457
54,087,743
61,381,496
62,117,949
61,467,698
60,345,531
59,440,709
68,969,825
73,081,068
66,238,169
62,259,160
63,479,984
66,309,708
67,152,890
76,702,821
81,168,684
71,183,413
80,852,386
78,784,863
71,857,620
72,714,221
75,183,371
70,851,705
82,781,757
88,080,264
94,700,566
83,400,641
106,648,601
89,549,056
99,074,296
99,074,29689,549,056106,648,60183,400,64194,700,56688,080,26482,781,75770,851,70575,183,37172,714,22171,857,62078,784,86380,852,38671,183,41381,168,68476,702,82167,152,89066,309,70863,479,98462,259,16066,238,16973,081,06868,969,82559,440,70960,345,53161,467,69862,117,94961,381,49654,087,74369,709,457045,467,48942,851,30943,511,47035,298,09236,486,86833,573,89931,413,42531,089,53135,520,645030,435,5590
       Other Current Liabilities 
94,894,660
42,453,929
70,796,587
48,673,004
50,505,022
41,695,972
62,841,284
38,341,497
53,785,663
47,284,954
59,626,601
56,525,967
106,148,212
49,553,691
57,897,569
53,697,693
57,988,900
61,250,368
73,658,031
112,881,565
104,445,248
85,155,403
85,514,750
84,208,296
33,505,075
37,072,116
45,492,280
71,310,023
80,917,191
77,257,660
87,958,680
85,016,524
159,071,271
125,574,191
136,728,776
117,348,875
124,515,179
119,070,179
132,856,635
133,940,695
0
152,040,068
0
0152,040,0680133,940,695132,856,635119,070,179124,515,179117,348,875136,728,776125,574,191159,071,27185,016,52487,958,68077,257,66080,917,19171,310,02345,492,28037,072,11633,505,07584,208,29685,514,75085,155,403104,445,248112,881,56573,658,03161,250,36857,988,90053,697,69357,897,56949,553,691106,148,21256,525,96759,626,60147,284,95453,785,66338,341,49762,841,28441,695,97250,505,02248,673,00470,796,58742,453,92994,894,660
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
236,063,244
341,556,947
340,988,499
347,667,869
347,313,079
344,974,056
260,856,571
344,909,207
350,385,516
270,873,763
355,385,429
252,112,440
269,041,977
347,326,531
345,057,554
349,286,156
344,979,215
290,731,723
200,466,803
200,466,803290,731,723344,979,215349,286,156345,057,554347,326,531269,041,977252,112,440355,385,429270,873,763350,385,516344,909,207260,856,571344,974,056347,313,079347,667,869340,988,499341,556,947236,063,244000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-396,917,806
-394,852,193
-396,139,874
-189,892,039
-89,936,158
-89,959,436
-189,873,645
-99,918,010
-199,864,886
-207,031,998
-104,180,100
-104,062,913
-94,938,022
4,217,529
4,083,391
8,628,532
7,546,616
7,523,553
8,442,185
8,194,363
7,995,398
7,816,688
7,890,554
7,729,713
8,198,268
4,530,158
4,341,620
4,268,261
4,268,2614,341,6204,530,1588,198,2687,729,7137,890,5547,816,6887,995,3988,194,3638,442,1857,523,5537,546,6168,628,5324,083,3914,217,529-94,938,022-104,062,913-104,180,100-207,031,998-199,864,886-99,918,010-189,873,645-89,959,436-89,936,158-189,892,039-396,139,874-394,852,193-396,917,806000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36,554,859
40,554,568
39,691,474
0
39,095,120
36,853,369
35,197,846
0
38,379,729
34,908,845
28,981,366
0
-1
0
-1
1
0
0
0
0001-10-1028,981,36634,908,84538,379,729035,197,84636,853,36939,095,120039,691,47440,554,56836,554,859000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,368,020
23,553,367
23,386,976
23,177,622
21,177,267
21,177,135
20,726,078
20,500,450
6,035,359
0
0
0
25,829,703
0
0
0
44,787,657
0
0
0
82,914,983
0
0
0
120,539,921
0
0
0
000120,539,92100082,914,98300044,787,65700025,829,7030006,035,35920,500,45020,726,07821,177,13521,177,26723,177,62223,386,97623,553,36723,368,020000000000000000
> Total Stockholder Equity
391,049,491
409,335,987
427,213,329
433,672,380
440,174,739
453,792,158
445,533,756
443,079,931
444,556,398
459,347,321
469,835,652
480,071,725
476,215,875
477,399,261
478,550,905
499,492,956
494,679,712
505,735,736
515,138,435
519,438,536
517,175,441
522,065,645
523,561,034
494,132,577
495,454,677
513,786,128
516,043,380
519,314,540
541,815,924
526,335,742
529,446,753
550,993,580
550,123,352
544,393,364
544,810,358
573,566,552
593,611,027
612,721,534
629,548,782
608,017,372
665,004,182
686,725,744
704,157,166
704,157,166686,725,744665,004,182608,017,372629,548,782612,721,534593,611,027573,566,552544,810,358544,393,364550,123,352550,993,580529,446,753526,335,742541,815,924519,314,540516,043,380513,786,128495,454,677494,132,577523,561,034522,065,645517,175,441519,438,536515,138,435505,735,736494,679,712499,492,956478,550,905477,399,261476,215,875480,071,725469,835,652459,347,321444,556,398443,079,931445,533,756453,792,158440,174,739433,672,380427,213,329409,335,987391,049,491
   Common Stock
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
28,966,438
0
28,966,438
0
028,966,438028,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,43828,966,438
   Retained Earnings Total Equity0000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000000000000000000
   Capital Surplus 0000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569-44,915,569
   Other Stockholders Equity 0-26,308,9800-28,465,506-18,567,839-14,254,304-18,352,959-31,741,820-29,658,853-18,831,156-16,954,657-2,634,983-1,432,286-4,169,510-6,167,162-6,856,780-7,357,905-7,804,731-7,701,623-9,362,434-11,137,819-9,346,544-8,876,054-3,186,276-1,298,602-1,698,284-2,576,238-643,359000000000000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,221,951,076
Cost of Revenue-613,737,995
Gross Profit608,213,081608,213,081
 
Operating Income (+$)
Gross Profit608,213,081
Operating Expense-1,088,544,324
Operating Income133,406,752-480,331,242
 
Operating Expense (+$)
Research Development145,349,740
Selling General Administrative225,351,852
Selling And Marketing Expenses0
Operating Expense1,088,544,324370,701,592
 
Net Interest Income (+$)
Interest Income1,126,761
Interest Expense-13,149,680
Other Finance Cost-1
Net Interest Income-12,022,920
 
Pretax Income (+$)
Operating Income133,406,752
Net Interest Income-12,022,920
Other Non-Operating Income Expenses0
Income Before Tax (EBT)111,631,243133,406,752
EBIT - interestExpense = -13,149,680
111,501,799
124,651,479
Interest Expense13,149,680
Earnings Before Interest and Taxes (EBIT)0124,780,923
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax111,631,243
Tax Provision-129,444
Net Income From Continuing Ops111,501,799111,501,799
Net Income111,501,799
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net012,022,920
 

Technical Analysis of Daewoong
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Daewoong. The general trend of Daewoong is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Daewoong's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Daewoong Pharma.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 127,600 < 129,700 < 138,500.

The bearish price targets are: 106,700 > 104,900 > 104,900.

Tweet this
Daewoong Pharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Daewoong Pharma. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Daewoong Pharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Daewoong Pharma.

Daewoong Pharma Daily Moving Average Convergence/Divergence (MACD) ChartDaewoong Pharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Daewoong Pharma. The current adx is .

Daewoong Pharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Daewoong Pharma.

Daewoong Pharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Daewoong Pharma.

Daewoong Pharma Daily Relative Strength Index (RSI) ChartDaewoong Pharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Daewoong Pharma.

Daewoong Pharma Daily Stochastic Oscillator ChartDaewoong Pharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Daewoong Pharma.

Daewoong Pharma Daily Commodity Channel Index (CCI) ChartDaewoong Pharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Daewoong Pharma.

Daewoong Pharma Daily Chande Momentum Oscillator (CMO) ChartDaewoong Pharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Daewoong Pharma.

Daewoong Pharma Daily Williams %R ChartDaewoong Pharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Daewoong Pharma.

Daewoong Pharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Daewoong Pharma.

Daewoong Pharma Daily Average True Range (ATR) ChartDaewoong Pharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Daewoong Pharma.

Daewoong Pharma Daily On-Balance Volume (OBV) ChartDaewoong Pharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Daewoong Pharma.

Daewoong Pharma Daily Money Flow Index (MFI) ChartDaewoong Pharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Daewoong Pharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-12WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Daewoong Pharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Daewoong Pharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose111,700.000
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Daewoong with someone you think should read this too:
  • Are you bullish or bearish on Daewoong? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Daewoong? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Daewoong Pharma

I send you an email if I find something interesting about Daewoong Pharma.


Comments

How you think about this?

Leave a comment

Stay informed about Daewoong Pharma.

Receive notifications about Daewoong Pharma in your mailbox!